CDXS Codexis Inc.

Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Date	Price Target	Rating	Analyst
8/19/2024		Buy → Hold	The Benchmark Company
6/3/2024	$5.00	Buy	Jefferies
5/30/2024	$11.00	Overweight	Cantor Fitzgerald
2/29/2024		Hold → Buy	The Benchmark Company
11/7/2023		Buy → Hold	The Benchmark Company
8/7/2023	$21.00 → $4.00	Outperform → Market Perform	TD Cowen
5/9/2023		Buy → Neutral	H.C. Wainwright
3/31/2022	$35.00	Overweight	Piper Sandler
3/2/2022		Outperform	Cowen
11/5/2021	$33.00 → $38.00	Buy	HC Wainwright & Co.

Codexis Inc.

Peers

Recent Analyst Ratings for Codexis Inc.

Codexis Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Opaleye Management Inc. bought $560,009 worth of shares (250,000 units at $2.24) (SEC Form 4)

Director Wolf Dennis P was granted 40,983 shares, increasing direct ownership by 38% to 147,903 units (SEC Form 4)

Director Smith David V was granted 40,983 shares, increasing direct ownership by 63% to 105,705 units (SEC Form 4)

Director Singhvi Rahul was granted 40,983 shares, increasing direct ownership by 43% to 137,052 units (SEC Form 4)

Director Richards Christos was granted 40,983 shares, increasing direct ownership by 93% to 85,133 units (SEC Form 4)

Director Parker H Stewart was granted 40,983 shares, increasing direct ownership by 40% to 143,583 units (SEC Form 4)

Director Martinborough Esther was granted 40,983 shares, increasing direct ownership by 47% to 129,036 units (SEC Form 4)

Director De Vre Raymond was granted 40,983 shares, increasing direct ownership by 86% to 88,829 units (SEC Form 4)

Director Collins Cynthia was granted 40,983 shares, increasing direct ownership by 58% to 112,157 units (SEC Form 4)

Large owner Opaleye Management Inc. bought $5,487,000 worth of shares (2,325,000 units at $2.36) (SEC Form 4)